NEW YORK (GenomeWeb) – Metabolon announced that it has partnered with Johns Hopkins University and Tufts Medical Center to develop and clinically validate a new test for diagnosing chronic kidney disease.
The test, called accuGFR, will be based on previous work by the collaborators evaluating hundreds of patient samples to verify novel metabolite markers of glomerular filtration rate (GFR) to assess kidney function.